Interim clinical results from ‘OPEN I’
study of the Stentys bifurcated stent to be reported at this week’s
‘EuroPCR 2008’
international cardiovascular meeting
PARIS (Business Wire EON) May 12, 2008 --
Medical device pioneer Stentys
announced today that clinical results from the ‘OPEN
I’ clinical study using its bifurcated
stent will be presented at this week’s ‘EuroPCR
2008’ international medical meeting on
cardiovascular intervention. The data, to be presented by Eberhard
Grube, M.D., Chief of Cardiology and Angiology at HELIOS Heart
Center (Germany) and Principal Investigator of the OPEN I study, will
look at safety results after 30 days post-implantation of the Stentys
bifurcated stent in the first 13 patients.
Dr. Grube will make his Stentys presentation during the ‘Glimpse
to the future’ session on bifurcations on
Thursday (May 15) morning.
The annual ‘EuroPCR’
medical meeting contributes to the advancement of education and
information about existing and new technologies in the fields of
cardiovascular intervention.
About Stentys
Based in Paris, Stentys intends to make treatment of blocked coronary
artery bifurcations as simple and effective as a conventional stenting
procedure. The Company has developed the world’s
first next-generation dedicated stent for treatment of blocked
coronary artery bifurcations that is designed so that hundreds of
thousands of patients might avoid open-chest surgery. To date, the
Stentys bifurcated stent has been successfully implanted in patients as
part of the OPEN 1 trial, taking routine interventional time to
complete; the patients were released from the ICU within hours of
implantation of the Stentys bifurcated stent and were discharged from
the hospital shortly after the procedure.
Post Comment:
Trackback URL: http://eon.businesswire.com/pingpr.php/Q291cC1Ib3JyLVRoaXItU3F1YS1DcmFzLVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
